Systemic reactions to immunotherapy during mountain cedar season: implications for seasonal dose adjustment

Wong, Priscilla H.; Quinn, James A.; Gomez, Robert; Webb, Charles N.

doi:10.1016/j.jaip.2017.03.021

Cited by 11 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…57 SCIT has also generally been found to be a safe treatment for SAR symptoms owing to mountain cedar. Wong et al 58 revealed that inseason pollen exposure to mountain cedar did not increase rates of systemic reaction (SR) with SCIT. Through a multiyear retrospective cohort study, the authors found no considerable differences for SR rates during both pollen season and out of season among patients with and without allergy to mountain cedar.…”

Section: Treatmentmentioning

confidence: 99%

“…Through a multiyear retrospective cohort study, the authors found no considerable differences for SR rates during both pollen season and out of season among patients with and without allergy to mountain cedar. 58 Dosage adjustment during in-season pollen exposure already carries an inherent risk in of itself, and this long-held practice may not be necessary for patients with mountain cedar SCIT.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Mountain cedar allergy

Mendoza

Quinn

2022

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Mountain cedar allergy

Mendoza

Quinn

2022

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

“…As mentioned, fatal and near-fatal anaphylactic events have been reported during peak pollen seasons [5,16,17]. In this regard, cautious dosing during peak pollen seasons is advisable, especially in patients who are highly sensitized (i.e., highly reactive skin prick tests), experience seasonally exacerbated asthma, or had prior systemic reactions to injections.…”

Section: How Best To Manage Risk For Subcutaneous Allergy Immunothera...mentioning

confidence: 99%

Is allergy immunotherapy-induced anaphylaxis still a real problem?

Bernstein

Berendts

2022

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…♦ Using a minimum of dose reductions, e.g., seasonal peak or missed appointment, can improve adherence without an increase in adverse events [65,66].…”

Section: Research Studies On Improving Ait Adherence: Key Findingsmentioning

confidence: 99%

Allergen Immunotherapy: Efficacy, Persistence, Consistency, and Cost Effectiveness

Wallace

Уоллес²

2018

Vestn. Ross. univ. družby nar., Ser. Med.

View full text Add to dashboard Cite

Although allergen immunotherapy (AIT) has been used for the treatment of allergic rhinitis (AR), allergic conjunctivitis, asthma, stinging insect hypersensitivity, and atopic dermatitis for over 100 years, it has been slow to gain universal acceptance. With the publication of the "World Health Organization Position Paper, Allergen Immunotherapy" in 1998 which summarized the scientific evidence for the efficacy and long-term benefit of this therapy, it has become an accepted and respected modality of treatment. In this review there are discussed following topics of allergen immunotherapy: the reasons for recommending AIT, mechanism of action, subcutaneous and sublingual methods of application, duration, adherence and cost effectiveness. It is necessary to support, not blame, the patient for nonadherence as it is the responsibility of the patient, the physician, and the health-care system to create an environment in which the patient can be adherent. Nonadherence is multifactorial in most every patient and the physician must address all of the factors if adherence is to be improved. The greatest challenge is taking the time to create an individualized patient-tailored strategy to improve adherence, as one size does not fit all. Adherence is dynamic and selecting the best time to start AIT and assuring that there is close follow-up through AIT years of treatment is essential. The patient who is persistent and consistent in year one of AIT may not continue to be so in year three without added encouragement and support. The health-care systems and professional organizations need to help train physicians and their staff both in efficient and accurate ways to assess nonadherence and in implementing interventions to optimize adherence. The multidisciplinary approach to treating this disease of nonadherence will require the involvement of all healthcare professionals, researchers, professional organizations, insurance companies, and policy-makers.

show abstract

Systemic reactions to immunotherapy during mountain cedar season: implications for seasonal dose adjustment

Cited by 11 publications

References 8 publications

Mountain cedar allergy

Mountain cedar allergy

Is allergy immunotherapy-induced anaphylaxis still a real problem?

Allergen Immunotherapy: Efficacy, Persistence, Consistency, and Cost Effectiveness

Contact Info

Product

Resources

About